Alexion Pharmaceuticals (NASDAQ:
ALXN) slips
4% premarket on modest volume in apparent reaction to Amgen’s
announced $13.4B acquisition of Celgene’s Otezla. Investors perceive that the deal dampens hopes for a
merger with the Thousand Oaks, CA-based biotech speculated by Intereconomy.com last week.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.